PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $835,885 | -51.8% | 50,113 | -20.2% | 0.00% | -50.0% |
| Q2 2023 | $1,735,475 | +98.6% | 62,834 | +65.3% | 0.00% | +100.0% |
| Q1 2023 | $874,023 | +156.5% | 38,001 | +21.7% | 0.00% | – |
| Q4 2022 | $340,796 | +26.2% | 31,237 | -2.5% | 0.00% | – |
| Q3 2022 | $270,000 | +7.6% | 32,032 | +0.7% | 0.00% | – |
| Q2 2022 | $251,000 | -67.8% | 31,815 | -3.3% | 0.00% | -100.0% |
| Q1 2022 | $779,000 | -19.6% | 32,898 | +16.1% | 0.00% | 0.0% |
| Q4 2021 | $969,000 | +97.4% | 28,348 | +2.4% | 0.00% | – |
| Q3 2021 | $491,000 | -60.1% | 27,695 | +0.9% | 0.00% | -100.0% |
| Q2 2021 | $1,231,000 | +124.2% | 27,455 | +29.3% | 0.00% | – |
| Q1 2021 | $549,000 | -46.4% | 21,240 | -58.2% | 0.00% | -100.0% |
| Q4 2020 | $1,025,000 | +90.9% | 50,823 | +85.0% | 0.00% | – |
| Q3 2020 | $537,000 | +50.0% | 27,476 | +62.3% | 0.00% | – |
| Q3 2016 | $358,000 | – | 16,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |